- Belgrade '18
- Vienna '18
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: G.Lesieur FRANCE
Back to previous
To study the cumulative Cystoid Macular Edema (CME) rate after 3345 implantations during cataract surgery of 4 different hydrophilic acrylic MICS lens.
Centre Ophtalmologique IRIDIS, Albi, France.
This retrospective study comprises all patients who were implanted between 2006 and 2011 with one of the after 4 micro-incision IOLs: Akreos MICS (Bausch and Lomb), CT Asphina (Zeiss), MicroSlim and Micro AY (PhysIOL). The postoperative follow-up ranged from 1 to 62 months. The cumulative incidence rates of Cystoid Macular Edema (CME) were determined by the Kaplan-Meier survival analysis. The Mann-Withney test was performed after 12 months with a significance threshold of 0.05.
The 1-year survival percentage (i.e. the percentage of no CME patients) was 95% for the CT Asphina (95% CI: 95-95); 96% for the Akreos MICS (94% CI: 92-97) ; 100% for the MicroSlim (95% CI: 100-100) and 100% for the Micro AY (95% CI: 100-100). The survival no CME curves provide different trends depending on the IOL type. The MicroSlim and MicroAY give similar outcomes with no statistically significant difference. In contrast, the difference was statically significant between the MicroAY (or MicroSlim) and the CT Asphina (p<0.007), as well as between the MicroAY (or MicroSlim) and the Akreos MICS (p<0.007). No statistically significant difference was observed between the CT Asphina and the MI60 (p>0.9). Existing comorbidities may explain the significant difference between IOLs
MICS is safe and reliable regarding cataract surgery. OMC rate is very low and can be explained most of the time by a comorbidity favoring the OMC appearance. The low occurrence of CME after implantation of micro-incision cataract surgery (MICS) IOLs was confirmed in this study. However, measured cumulative CME rates seemed perhaps to depend on the IOL design rather than on the biomaterial.
... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company